Conditions: Kidney Cancer Melanoma (Skin) Metastatic Cancer
Keywords: stage IV melanoma tumors metastatic to brain stage IV renal cell cancer recurrent melanoma recurrent renal cell cancer
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 8
Healthy volunteers: no

Brief summary:
RATIONALE: Sunitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.

PURPOSE: This phase II trial is studying how well sunitinib works in treating patients with brain metastases caused by kidney cancer or melanoma.

Detailed description:
OBJECTIVES:

Primary

* Determine the efficacy of sunitinib malate, in terms of objective radiographic response of brain lesions, in patients with brain metastases secondary to renal cell carcinoma or melanoma.

Secondary

* Determine overall and progression-free survival.

OUTLINE: Patients receive oral sunitinib malate once daily on days 1-28. Courses repeat every 6 weeks for up to 1 year in the absence of disease progression or unacceptable toxicity.

After completion of study therapy, patients are followed periodically.

Arms:
arm 1: Patients will be treated with 50 mg daily for four out of every six weeks.

Interventions: intervention 1: sunitinib malate
Intervention descriptions: intervention 1: None

Protocol document: